A May 21, 2026, notice to licensees from the Alabama Board of Medical Examiners addresses research-grade and non-FDA-approved peptides, including state formulary limits for CNMs, CRNPs, and PAs.
Notice to Licensees Details Prescribing Limits for Research-Grade Peptides
On May 21, 2026, the Alabama Board of Medical Examiners issued a notice to licensees addressing the prescribing and use of non-FDA-approved, research-grade peptides. The notice limits physician use, restricts delegation by practitioners, and clarifies formulary status for CNMs, CRNPs, and PAs. The action is directly relevant to Alabama wellness, weight-loss, and Med Spa–adjacent clinic models that encounter peptide-based services.
Licensee Notice Addresses Research-Grade Peptides and Alabama Formularies
In a May 21, 2026, notice to licensees, the Alabama Board of Medical Examiners addressed the prescribing and use of non-FDA-approved, research-grade peptides in Alabama. The notice states that research-grade peptides are not FDA-approved and have not been tested, reviewed, or determined by the FDA to be safe or effective for human use.
The licensee notice also states that drugs administered or dispensed to patients must meet prescription-quality standards. It says Alabama physicians must obtain prescription products, drugs, and ingredients from entities permitted by the Alabama State Board of Pharmacy.
According to the notice, Alabama physicians may not bring research-grade or non-FDA-approved peptides into patient care through prescribing, compounding, administration, dispensing, supply, recommendations, or related clinical advice. The notice also states that physicians may not route the purchase, administration, or dispensing of those products through CNMs, CRNPs, or PAs. It also discusses waiver language, stating that patient consent cannot remove a provider’s duty of care or obligation to comply with the law. The notice says forms identifying a product as “research-grade” do not reduce or eliminate professional or legal liability.
Separately, the FDA has recently addressed peptide-related bulk drug substances in the 503A compounding context. On April 22, 2026, the FDA removed 12 peptides from Category 2 after the nominations were withdrawn. The agency also lists certain peptide-related bulk drug entries that may pose significant safety risks, including concerns about immunogenicity, impurities, limited safety information, and active pharmaceutical ingredient characterization. The agency has scheduled a discussion of several of those entries by the Pharmacy Compounding Advisory Committee on July 23–24, 2026.
Source: Alabama Licensee Notice and FDA 503A Update
According to a May 21, 2026, notice to licensees from the Alabama Board of Medical Examiners, the board addressed research-grade and non-FDA-approved peptides in Alabama. The notice was distributed to active licensees, certificate holders, and permit holders and was not publicly linked at the time of publication. The FDA’s April 22, 2026, 503A peptide update and July 23–24, 2026, Pharmacy Compounding Advisory Committee meeting notice provide separate federal-level context.
Compliance Context for Research-Grade Peptides in Alabama
Alabama law sets provider-specific prescribing pathways for CRNPs, CNMs, and PAs. Under Alabama Code §§ 34-21-86 and 34-24-292, those pathways involve approved protocols, job descriptions, and applicable formularies. The May 21 licensee notice applies those prescribing pathways to products labeled or used as research-grade peptides. The formulary point is central because the notice states that no research-grade or non-FDA-approved peptide is included on an approved formulary for CNMs, CRNPs, or PAs. It also states that physicians may not use delegation to route the purchase, administration, or dispensing of those products through those practitioners.
A related Alabama Attorney General action adds public enforcement context. In November 2025, the Attorney General filed suit against Aurora IV and Wellness, alleging the Cullman IV infusion clinic advertised tirzepatide and semaglutide as “pharmaceutical-grade” while administering research-grade versions that were not approved for human use. The Attorney General’s Office said the Alabama Board of Medical Examiners assisted in that investigation.
The licensee notice also relates to broader weight-loss medication oversight. FDA warning letters sent in February 2026 addressed false or misleading claims involving compounded GLP-1 products marketed through online clinical programs. The overlap involves product claims, prescribing practices, and patient-facing representations for non-FDA-approved or compounded products.
For Med Spa operators in Alabama, the licensee notice is relevant to peptide injections, weight-loss services, IVs or wellness protocols, delegated administration, off-formulary products, and products labeled for research use. Operators that prescribe, source, handle, administer, or delegate those services remain subject to current Alabama prescribing, sourcing, formulary, and delegation requirements.
Practical Considerations for Alabama Med Spa Operators
- Confirm that CNM, CRNP, and PA roles align with applicable Alabama protocols, job descriptions, and approved formularies.
- Audit peptide, weight-loss, IV, and wellness service menus for products labeled or sourced as research-grade or non-FDA-approved peptides.
- Validate that peptide-related products are obtained through prescription-quality sourcing channels permitted under Alabama requirements.
- Review physician delegation records for peptide-related sourcing, prescribing, administration, dispensing, recommendations, or supply.
- Maintain documentation that shows the product source, prescriber authority, formulary status, patient consent language, and provider role for peptide-related services.
Peptide Oversight Developments to Monitor
The Alabama Board of Medical Examiners may issue additional guidance, take disciplinary action, or update the formulary following this notice. Separately, the FDA’s Pharmacy Compounding Advisory Committee will review several peptide-related bulk drug substances at its July 23–24, 2026, meeting under the 503A process, which may further clarify federal compounding eligibility for specific peptides.
About Spakinect
Spakinect provides compliance infrastructure and telehealth-supported supervision solutions for medical aesthetic practices. For additional information, see our website.
Image Attribution: “Alabama State House, Montgomery, West view” by DXR, via Wikimedia Commons, licensed under CC BY-SA 4.0.
